Nation, Migration, Identity: Learning from the Cross-Strait Context

It has been argued that globalisation, with its flexible landscapes of production, consumption and mobility, has favoured the emergence of new forms of belonging and identity that are not necessarily built on such principles of the nation state. In this paper, we argue that this process is more likely to happen when movements occur between states that are not in conflictual relations with each other. When the relations between two nations are shaped by conflicts, for instance due to disputes about sovereignty over a territory, nationalism may remain a crucial factor shaping identification and belonging of those who move between the two territories. In this paper, by taking the case of migrants moving between the People’s Republic of China and Taiwan, we will shed light on how the issue of “unresolved sovereignty” may eventually lead these actors to reinforce nationalist ideals and identities in their daily narratives and practices, instead of favouring the generation of hybrid identities

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Testing GNC technologies for planetary landing on Mars and Moon analogues

In the frame of the ESA Aurora exploration program the precision landing on Mars and Moon is of strategic importance because the ability to land on sites with high scientific interest is not a straightforward task. From here the need to provide a dedicated test facility able to test GNC techniques and technologies both vision and LIDAR based in a realistic environment which is of paramount importance for the representatively of the real descent scenario seen by the GNC sensors, in real time and in a real scale. This is a fundamental step through which the planetary exploration will pass through in order to reduce the inherent risks associated to any landing mission. The ESA funded project named Precision Landing GNC Test Facility has been conceived with this purpose and it is successfully started; the test facility will emulate a real lander dynamics during the powered descent phase that is last part of the descent phase including landing. PLGTF is approaching to be the first ever-built facility with such a performances and it will be able to validate the entire GNC chain of a landing system. The first PLGTF implementation foresees the capability to validate the Navigation function of a GNC system including the sensor/s associated to it through the execution of predefined descent trajectories. Consequently it will be presented the first edition of the PLGTF focussing the attention to the validation of the navigation function of the ESA NPAL experiment. In a near future, an enhanced version of the PLGTF will enable to validate Guidance algorithms and Hazard Avoidance techniques through the execution of closed loop tests and consequently testing the precision landing and the pinpointing capabilities

Mars and moon exploration passing through the european precision landing GNC test facility

In the frame of the ESA Aurora exploration program, the precision landing on Mars and Moon is of strategic importance because the ability to land on sites with high scientific interest is not a straightforward task. From here is the need to provide a dedicated test facility able to test Guidance, Navigation and Control (GNC) techniques and technologies, both vision and LIDAR based, in a realistic environment, in real time and as much as possible in a real scale. This is a fundamental step through which the planetary exploration will pass through in order to reduce the inherent risks associated with any landing mission. The ESA project named Precision Landing GNC Test Facility (PLGTF) has been conceived with this purpose, has been successfully started and, at the time of writing of the paper, has reached the detailed design phase. PLGTF will emulate a real lander dynamics during the powered descent phase in an atmospheric and non-atmospheric planetary environment, minimising the unavoidable scale factor to be applied. PLGTF is going to be the first ever-built facility with such a performance and it will be able to validate the entire GNC chain of a planetary landing system. The paper describes the PLGTF configuration for what concerns its first implementation, mainly devoted to validate the navigation function of a vision-based landing system and the associated sensor, and will also provide some preliminary information on the planned enhancements

Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease

OBJECTIVES: Disease course in inflammatory bowel disease (IBD) is variable and difficult to predict. To optimize prognosis, it is of interest to identify phenotypic characteristics at disease onset and other prognostic factors that predict disease course. The aim of this study was to evaluate such factors in a population-based IBD group. METHODS: IBD patients diagnosed between 1 January 1991 and 1 January 2003 were included. A follow-up questionnaire was developed and medical records were reviewed. Patients were classified according to phenotype at diagnosis and risk factors were registered. Disease severity, cumulative medication use, and "surgical" and "nonsurgical" recurrence rates were calculated as outcome parameters. RESULTS: In total, 476 Crohn's disease (CD), 630 ulcerative colitis (UC), and 81 indeterminate colitis (IC) patients were diagnosed. In CD (mean follow-up 7.6 years), 50% had undergone resective surgery. In UC (mean follow-up 7 years), colectomy rate was 8.3%. First year cumulative recurrence rates per 100 patient-years for CD, UC, and IC were 53, 44, and 42%, respectively. In CD, small bowel localization and stricturing disease were negative prognostic factors for surgery, as was young age. Overall recurrence rate was increased by young age and current smoking. In UC, extensive colitis increased surgical risk. In UC, older age at diagnosis initially increased recurrence risk but was subsequently protective. CONCLUSIONS: This population-based IBD study showed high recurrence rates in the first year. In CD, small bowel localization, stricturing disease, and young age were predictive for disease recurrence. In UC, extensive colitis and older age at diagnosis were negative prognostic predictors

Fatigue and health-related quality of life in inflammatory bowel disease: Results from a population-based study in the Netherlands: The IBD-South Limburg cohort.

BACKGROUND:: The importance of fatigue in chronic disease has been increasingly recognized; however, little is known about fatigue in inflammatory bowel disease (IBD). The aim of the present study was to investigate the prevalence and severity of fatigue and the impact on health-related quality of life (HRQoL) in patients included in a population-based IBD cohort in the Netherlands. METHODS:: IBD patients, diagnosed between January 1st, 1991, and January 1st, 2003, were followed up for a median of 7.1 years. They completed a questionnaire, which included a disease activity score, the Multidimensional Fatigue Inventory (MFI-20), the Inflammatory Bowel Disease Questionnaire (IBDQ), and the Short Form health survey (SF-36). Hemoglobin levels were recorded. RESULTS:: Data were available in 304 Crohn's disease (CD), 368 ulcerative colitis (UC), and 35 indeterminate colitis (IC) patients. During quiescent disease, the prevalence of fatigue was nearly 40%. MFI-20 and HRQoL scores were significantly worse in IBD patients having active disease. In a multivariate analysis, disease activity was positively related with the level of fatigue in both CD and UC. In UC, anemia influenced the general fatigue score independently of disease activity. Disease activity as well as fatigue were independently associated with an impaired IBDQ. CONCLUSIONS:: In IBD, even in remission, fatigue is an important feature. Both in CD and in UC, fatigue determined HRQoL independently of disease activity or anemia. This implies that in IBD patients physicians need to be aware of fatigue in order to better understand its impact and to improve the HRQoL. (Inflamm Bowel Dis 2010)

Broadly Applicable, Virus-Free Dual Reporter Assay to Identify Compounds Interfering with Membrane Fusion: Performance for HSV-1 and SARS-CoV-2

Membrane fusion constitutes an essential step in the replication cycle of numerous viral pathogens, hence it represents an important druggable target. In the present study, we established a virus-free, stable reporter fusion inhibition assay (SRFIA) specifically designed to identify compounds interfering with virus-induced membrane fusion. The dual reporter assay is based on two stable Vero cell lines harboring the third-generation tetracycline (Tet3G) transactivator and a bicistronic reporter gene cassette under the control of the tetracycline responsive element (TRE3G), respectively. Cell–cell fusion by the transient transfection of viral fusogens in the presence of doxycycline results in the expression of the reporter enzyme secreted alkaline phosphatase (SEAP) and the fluorescent nuclear localization marker EYFPNuc. A constitutively expressed, secreted form of nanoluciferase (secNLuc) functioned as the internal control. The performance of the SRFIA was tested for the quantification of SARS-CoV-2- and HSV-1-induced cell–cell fusion, respectively, showing high sensitivity and specificity, as well as the reliable identification of known fusion inhibitors. Parallel quantification of secNLuc enabled the detection of cytotoxic compounds or insufficient transfection efficacy. In conclusion, the SRFIA reported here is well suited for high-throughput screening for new antiviral agents and essentially will be applicable to all viral fusogens causing cell–cell fusion in Vero cells